Related Experiment Videos
Hyperuricemia in kidney transplantation.
Norberto Perico1, Igor Codreanu, Mariarosa Caruso
1Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Contributions to Nephrology
|December 18, 2004
Summary
Hyperuricemia is common in kidney transplant patients due to cyclosporine (CsA), which reduces uric acid clearance. Managing this condition is challenging and may impact graft function.
Area of Science:
- Nephrology
- Pharmacology
- Transplantation
Background:
- Hyperuricemia is a frequent complication in renal transplant recipients.
- Cyclosporine (CsA) is a primary contributor to hyperuricemia in this population.
- The exact mechanism by which CsA induces hyperuricemia is not fully understood but may involve renal tubular transport.
Purpose of the Study:
- To investigate the prevalence and contributing factors of hyperuricemia in renal transplant recipients.
- To understand the impact of hyperuricemia on renal graft function.
- To highlight the therapeutic challenges in managing hyperuricemia in this patient group.
Main Methods:
- Review of existing literature on hyperuricemia in renal transplant recipients.
- Analysis of factors contributing to hyperuricemia, including medication effects (CsA).
- Discussion of the potential mechanisms of CsA-induced hyperuricemia.
Main Results:
- Cyclosporine (CsA) significantly lowers the urinary clearance of uric acid.
- Hyperuricemia is linked to other risk factors in individual patients.
- The precise mechanism of CsA's effect on uric acid clearance requires further elucidation, potentially involving tubular alterations.
Conclusions:
- Hyperuricemia is a significant concern in renal transplant recipients, primarily driven by CsA.
- Hyperuricemia can exacerbate graft dysfunction and potentially lead to graft loss.
- Treatment of hyperuricemia in transplant patients presents unique therapeutic difficulties.